2355 related articles for article (PubMed ID: 30144694)
1. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
[TBL] [Abstract][Full Text] [Related]
2. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
Juryńczyk M; Tackley G; Kong Y; Geraldes R; Matthews L; Woodhall M; Waters P; Kuker W; Craner M; Weir A; DeLuca GC; Kremer S; Leite MI; Vincent A; Jacob A; de Sèze J; Palace J
J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):132-136. PubMed ID: 27951522
[TBL] [Abstract][Full Text] [Related]
3. Clinical and MRI measures to identify non-acute MOG-antibody disease in adults.
Cortese R; Battaglini M; Prados F; Bianchi A; Haider L; Jacob A; Palace J; Messina S; Paul F; Wuerfel J; Marignier R; Durand-Dubief F; de Medeiros Rimkus C; Callegaro D; Sato DK; Filippi M; Rocca MA; Cacciaguerra L; Rovira A; Sastre-Garriga J; Arrambide G; Liu Y; Duan Y; Gasperini C; Tortorella C; Ruggieri S; Amato MP; Ulivelli M; Groppa S; Grothe M; Llufriu S; Sepulveda M; Lukas C; Bellenberg B; Schneider R; Sowa P; Celius EG; Proebstel AK; Yaldizli Ö; Müller J; Stankoff B; Bodini B; Carmisciano L; Sormani MP; Barkhof F; De Stefano N; Ciccarelli O;
Brain; 2023 Jun; 146(6):2489-2501. PubMed ID: 36515653
[TBL] [Abstract][Full Text] [Related]
4. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.
Jurynczyk M; Geraldes R; Probert F; Woodhall MR; Waters P; Tackley G; DeLuca G; Chandratre S; Leite MI; Vincent A; Palace J
Brain; 2017 Mar; 140(3):617-627. PubMed ID: 28364548
[TBL] [Abstract][Full Text] [Related]
5. Brain lesion distribution criteria distinguish demyelinating diseases in China.
Cai MT; Zhang YX; Zheng Y; Yang F; Fang W; Shen CH; Ding MP
Ann Clin Transl Neurol; 2019 Oct; 6(10):2048-2053. PubMed ID: 31566925
[TBL] [Abstract][Full Text] [Related]
6. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
7. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
[TBL] [Abstract][Full Text] [Related]
9. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
[TBL] [Abstract][Full Text] [Related]
10. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
11. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
Ramanathan S; Prelog K; Barnes EH; Tantsis EM; Reddel SW; Henderson AP; Vucic S; Gorman MP; Benson LA; Alper G; Riney CJ; Barnett M; Parratt JD; Hardy TA; Leventer RJ; Merheb V; Nosadini M; Fung VS; Brilot F; Dale RC
Mult Scler; 2016 Apr; 22(4):470-82. PubMed ID: 26163068
[TBL] [Abstract][Full Text] [Related]
12. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y
Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
[TBL] [Abstract][Full Text] [Related]
13. Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?
Papais Alvarenga RM; Araújo ACRAE; Nascimento ACB; Araujo NEC; Meneguette NS; Neri VC; Papais Alvarenga M; Filho HA; Barros PO; Bento CA; Schmidt SL; Vasconcelos CCF; Alvarenga MP
Mult Scler Relat Disord; 2020 Jul; 42():102082. PubMed ID: 32361664
[TBL] [Abstract][Full Text] [Related]
14. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD
Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678
[TBL] [Abstract][Full Text] [Related]
15. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
16. Clinical and MRI phenotype of children with MOG antibodies.
Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
[TBL] [Abstract][Full Text] [Related]
17. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
Cai MT; Zheng Y; Shen CH; Yang F; Fang W; Zhang YX; Ding MP
Mult Scler; 2021 May; 27(6):871-882. PubMed ID: 32672091
[TBL] [Abstract][Full Text] [Related]
19. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
20. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
